Oncotelic Therapeutics, Inc. OTLC
Slide the table for earlier years · "·" marks a figure not available in our data for that year.
What this company does
Written from the business description in Oncotelic Therapeutics, Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 15 April 2026. Every sentence was checked against that document before publication.
Growth
Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.
Profitability
Each USD of equity produced 184 cents of profit this year.
The 17-year record
EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue $B | ◌ | ◌ | 0.0 | ◌ | ◌ | 0.0 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | 0.0 | 0.0 | ◌ | ◌ | ◌ |
| Operating income $B | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| EBITDA $B | ◌ | ◌ | ◌ | ◌ | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Income tax $B | 0.1 | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | 0.0 | 0.0 | ◌ | ◌ | ◌ | ◌ |
| Net income $B | 0.2 | −0.0 | −0.0 | 0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 | −0.0 |
| Free cash flow $B | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | −0.0 | −0.0 | ◌ | ◌ | ◌ | ◌ | −0.0 |
| EPS, diluted $ | 0.59 | −0.01 | −0.02 | 0.01 | −0.03 | −0.11 | −0.11 | −0.12 | −0.52 | −0.51 | −0.54 | −0.75 | −4.67 | −5.48 | −10.37 | −71.60 | −13.15 |
| Dividend / sh $ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ | ◌ |
| Payout % — not applicable: no dividend | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| ROE % | 184.0 | −44.4 | −50.1 | 37.2 | −95.2 | −66.3 | −68.6 | — | — | −72.1 | −50.2 | −72.2 | −156.3 | −121.1 | — | — | −426.4 |
| Shares out B | 0.44 | 0.41 | 0.40 | 0.39 | 0.38 | 0.09 | 0.08 | 0.04 | 0.03 | 0.03 | 0.03 | 0.02 | 0.01 | 0.00 | 0.02 | 0.01 | ◌ |
Slide the table for earlier years. "—" not applicable · "◌" not available in our data.
Company facts, as filed
Reconciled in 17 of the 17 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011.